WT1 and neoplasm: A large relatively recent investigation of WT1 protein expression used both polyclonal (C-19) and monoclonal (6F-H2) IHC antibodies on 494 human neoplasms of diverse origins (gastrointestinal/pancreatobiliary system, male/female urogenital system, mamary, pulmonary, cerebral, skin, soft tissues and bone).